(TGTX)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
TG Therapeutics, Inc., tijorat bosqichidagi biofarmatsevtika kompaniyasi, AQSh va xalqaro miqyosda B-hujayralari vositachiligidagi kasalliklarni davolashning yangi usullarini sotib olish, ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya kattalardagi MS (MS) ning qaytalanish shakllari, shu jumladan klinik izolyatsiya qilingan sindrom, remittent-remittent kasalligi va kattalardagi faol ikkilamchi progressiv kasallikni davolash uchun CD20 ga qarshi monoklonal antitelani bo'lgan BRIUMVI ni taqdim etadi. Kompaniyaning ishlab chiqarish quvvati qaytalanish MS ni davolash uchun glycoengineered anti-CD20 mAb bo'lgan Ublituximab IV ni o'z ichiga oladi; TG-1701 in vitro kinaza skriningida BTK ga nisbatan selektivlikni ko'rsatadigan og'iz orqali qabul qilinadigan va kovalent bog'langan Bruton tirozin kinaza (BTK) inhibitori; va TG-1801, bispesifik CD47 va CD19 antitelasi. Uning tadqiqot quvvati turli xil tadqiqot dori vositalarini o'z ichiga oladi. Kompaniya LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; va Jiangsu Hengrui Medicine Co. bilan litsenziyalash shartnomalariga ega. Kompaniya 1993 yilda tashkil etilgan va Shimoliy Karolina shtatining Morrisville shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. Adam Waldman | Chief Commercialization Officer |
| Mr. Michael S. Weiss Esq., J.D. | Chairman, CEO & President |
| Mr. Sean A. Power CPA | CFO, Corporate Secretary & Treasurer |
| Ms. Jenna Bosco | Senior Vice President of Corporate Communications |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-20 | 8-K | tgtx20260319_8k.htm |
| 2026-01-13 | 8-K | tgtx20260113_8k.htm |
| 2025-11-05 | 10-Q | tgtx20250930_10q.htm |
| 2025-11-03 | 8-K | tgtx20250909_8k.htm |
| 2025-08-08 | S-8 | tgtx20250722_s8.htm |
| 2025-08-04 | 8-K | tgtx20250724_8k.htm |
| 2025-06-13 | 8-K | tgtx20250613_8k.htm |
| 2025-05-09 | 10-Q | tgtx20250331_10q.htm |
| 2025-05-05 | 8-K | tgtx20250502_8k.htm |
| 2025-04-30 | ARS | tgtars.pdf |